Back to Search

A Phase 1/2, Multicenter, Open-Label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 as Monotherapy and in Combination Regimens, With Randomized Comparison to Investigator's Choice of Treatment, in Subjects With Metastatic Castration-resistant Prostate Cancer Who Are Resistant or Refractory to Prior Standard Therapies


  • Protocol Number: 202104073
  • Principal Investigator: Pachynski, Russell
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions